Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Cue Biopharma, Inc. (CUE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M | — |
| Research & development | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M | $33.5M | $27.5M | $28.5M | $18.9M |
| Operating expenses | $54.0M | $50.8M | $57.6M | $54.5M | $58.7M | $48.2M | $40.2M | $39.8M | $23.2M |
| Operating income | −$26.6M | −$41.5M | −$52.1M | −$53.2M | −$43.7M | −$45.0M | −$36.8M | −$38.7M | −$23.2M |
| EBITDAderived | −$25.6M | −$41.1M | −$51.6M | −$52.3M | −$42.5M | −$44.0M | −$36.0M | −$37.9M | — |
| Net income | −$26.6M | −$40.7M | −$50.7M | −$53.0M | −$44.2M | −$44.8M | −$36.7M | −$39.0M | −$23.2M |
| Basic EPSper diluted share | -$0.28 | -$0.72 | -$1.11 | -$1.49 | -$1.41 | -$1.56 | -$1.66 | -$1.94 | -$2.16 |
| Diluted EPSper diluted share | -$0.28 | -$0.72 | -$1.11 | -$1.49 | -$1.41 | -$1.56 | -$1.66 | -$1.94 | -$2.16 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 | Lin Shao-LeeChief Executive Officer | BuyCommon Stock Warrants (Right to Buy) · derivative · indirect | 45.5K | — | — | 45.5K |
| Jun 1, 2026Form 4 | Lin Shao-LeeChief Executive Officer | BuyPre-Funded Warrants (Right to Buy) · derivative · indirect | 90.9K | $11.00 | $1000.0K | 90.9K |
| Dec 30, 2025Form 4 | Sarraf PashaDirector | BuyCommon Stock | 77.4K | $0.30 | $23.2K | 323.9K |
| Dec 30, 2025Form 4 | Sarraf PashaDirector | BuyCommon Stock | 78.1K | $0.31 | $24.2K | 246.4K |
| Dec 30, 2025Form 4 | Sarraf PashaDirector | BuyCommon Stock | 86.9K | $0.32 | $27.8K | 168.3K |